OSI, Aveo Development Deal To Focus On EMT Mechanisms In Cancer
This article was originally published in The Pink Sheet Daily
Executive Summary
Collaboration aims to position OSI as a leader in the emerging area of epithelial-mesenchymal transition, CEO Goddard says.
You may also be interested in...
OSI Bullish On Increased Tarceva Sales
Oncologic is “entrenched” in the market, not greatly vulnerable to competition from Erbitux, CEO Goddard tells investors.
OSI Bullish On Increased Tarceva Sales
Oncologic is “entrenched” in the market, not greatly vulnerable to competition from Erbitux, CEO Goddard tells investors.
Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers
Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million